Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study

Abstract

BackgroundCurrent levels and dangers of opioid use in the U.S. warrant the investigation of harm-reducing treatment alternatives.PurposeA preliminary, historical, cohort study was used to examine the association between enrollment in the New Mexico Medical Cannabis Program (MCP) and opioid prescription use.MethodsThirty-seven habitual opioid using, chronic pain patients (mean age = 54 years; 54% male; 86% chronic back pain) enrolled in the MCP between 4/1/2010 and 10/3/2015 were compared to 29 non-enrolled patients (mean age = 60 years; 69% male; 100% chronic back pain). We used Prescription Monitoring Program opioid records over a 21 month period (first three months prior to enrollment for the MCP patients) to measure cessation (defined as the absence of opioid prescriptions activity during the last three months of observation) and reduction (calculated in average daily intravenous [IV] morphine dosages). MCP patient-reported benefits and side effects of using cannabis one year after enrollment were also collected.ResultsBy the end of the 21 month observation period, MCP enrollment was associated with 17.27 higher age- and gender-adjusted odds of ceasing opioid prescriptions (CI 1.89 to 157.36, p = 0.012), 5.12 higher odds of reducing daily prescription opioid dosages (CI 1.56 to 16.88, p = 0.007), and a 47 percentage point reduction in daily opioid dosages relative to a mean change of positive 10.4 percentage points in the comparison group (CI -90.68 to -3.59, p = 0.034). The monthly trend in opioid prescriptions over time was negative among MCP patients (-0.64mg IV morphine, CI -1.10 to -0.18, p = 0.008), but not statistically different from zero in the comparison group (0.18mg IV morphine, CI -0.02 to 0.39, p = 0.081). Survey responses indicated improvements in pain reduction, quality of life, social life, activity levels, and concentration, and few side effects from using cannabis one year after enrollment in the MCP (ps<0.001).ConclusionsThe clinically and statistically significant evidence of an association between MCP enrollment and opioid prescription cessation and reductions and improved quality of life warrants further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain.

Will medical cannabis treatment reduce pharmaceutical residues in the aquatic environment? A case study from an elderly nursing home

“…Symptom relief as a result of MC treatment was prominent and distinctly noticeable for most of the patients. Relief of symptoms such as pain, anxiety, moodiness, and spasticity was evident, agreeing well with many previous studies [22,24,25,[32][33][34] . Relief was obtained not only for the specific indications serving as criteria for each patient, but also for additional symptoms and side effects (e.g., sleep disorders, ataxia, depression, and lack of appetite), as shown previously by Boehnke et al (2016).…”

Medical marijuana and workers' compensation claiming

“…The clinical trial literature suggests that marijuana is an effective treatment for symptoms associated with a range of conditions including anxiety, chronic pain, depression, psychosis, sleep disorders, and spasticity (Joy, Watson, & Benson, ; Lynch & Campbell, ; Hill, ; Whiting et al, ; National Academies of Sciences, Engineering, & Medicine., ). Surveyed patients state that marijuana is effective (Reiman, Welty, & Solomon, ; Vigil, Stith, Adams, & Reeve, ).…”

Medical and non‐medical cannabis use and risk of prescription opioid use disorder: Findings from propensity score matching

“…Recent individual‐level studies addressed some limitations in Olfson et al . by examining prescription opioid and medical cannabis use among chronic pain patients . Substitution patterns from prescription opioids to medical cannabis were common in this population.…”